Specialties

Question 1

Repatha: generic name?

Answer 1

Evolocumab

Question 2

Evolocumab: brand name?

Answer 2

Repatha

Question 3

Repatha: indication(s)?

Answer 3

Hypercholesterolemia

Question 4

Repatha: mechanism of action?

Answer 4

PCSK9 inhibitor.
PCSK9 connects to the LDL-R and prevents its recycling to the hepatocyte surface, thus decreasing LDL-R on hepatocytes. Inhibiting PCSK9 increases LDL-R amount on hepatocyte surface.

Question 5

Repatha: partner?

Answer 5

Amgen

Question 6

Repatha: main competition?

Answer 6

Praluent (Alirocumab), 80% of Israeli market share

Question 7

Tepezza: generic name?

Answer 7

Teprotumumab

Question 8

Teprotumumab: brand name?

Answer 8

Tepezza

Question 9

Tepezza: Indication(s)?

Answer 9

Thyroid eye disease (TED)

Question 10

Tepezza: partner?

Answer 10

Amgen

Question 11

Tepezza: administration?

Answer 11

IV, once every 3 weeks, for a total of 8 infusions.

Question 12

Prolia: generic name?

Answer 12

Denosumab

Question 13

Denosumab: brand name?

Answer 13

Prolia

Question 14

Prolia: partner?

Answer 14

Amgen

Question 15

Prolia: Indication(s)?

Answer 15

Osteoporosis

Question 16

Prolia: mechanism of action?

Answer 16

RANK Ligand inhibitor - decreasing osteoclast activity and survival

Question 17

Prolia: administration?

Answer 17

S/C, once every 6 months

Question 18

Prolia: main competition?

Answer 18

Aclasta (zoledronic acid)

Question 19

Evenity: generic name?

Answer 19

Romosozumab

Question 20

Romosozumab: brand name?

Answer 20

Evenity

Question 21

Evenity: partner?

Answer 21

Amgen

Question 22

Evenity: indication(s)?

Answer 22

Osteoporosis

Question 23

Evenity: Mechanism of action?

Answer 23

Sclerostin inhibitor (monoclonal antibody).
Dual effect - both increasing osteoblastic activity and decreasing osteoclastic activity.

Question 24

Evenity: administration?

Answer 24

S/C, once a month for 12 months.

Question 25

Trikafta: generic name(s)?

Answer 25

Elexacaftor / Tezacaftor / Ivacaftor, and Ivacaftor

Question 26

Trikafta: indication(s)?

Answer 26

CF above age 2y, with at least one F508del mutation

Question 27

Trikafta: mechanism of action?

Answer 27

Elexacaftor and Tezacaftor improve cellular processing of CFTR so more reach the cell membrane; Ivacaftor improves open channel probability (gating).

Question 28

Trikafta: administration?

Answer 28

PO, daily. Combination at morning + Ivacaftor at evening.

Question 29

Trikafta: partner?

Answer 29

Vertex

Question 30

Elafibrinor: Indication(s)?

Answer 30

Primary Biliary Cholangitis (PBC)

Question 31

Elafibrinor: Partner?

Answer 31

Ipsen

Question 32

Elafibrinor: administration?

Answer 32

PO

Question 33

Elafibranor: mechanism of action?

Answer 33

Dual PPAR-alpha and PPAR-delta agonist

Question 34

Bylvay: generic name?

Answer 34

Odevixibat

Question 35

Odevixibat: brand name?

Answer 35

Bylvay

Question 36

Bylvay: partner?

Answer 36

Ipsen

Question 37

Bylvay: indication(s)?

Answer 37

1. Progressive Familial Intrahepatic Cholestasis (PFIC) > 6 months of age 2. Alagille syndrome >12 months of age

Question 38

Bylvay: administration?

Answer 38

PO, once daily

Question 39

Bylvay: mechanism of action?

Answer 39

Ileal Bile Acid Transporter (IBAT) inhibitor, decreasing bile acid reabsorption and increasing its fecal excretion